<DOC>
	<DOC>NCT00454649</DOC>
	<brief_summary>To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.</brief_summary>
	<brief_title>Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Advanced solid tumors suitable for treatment with Taxanes, with or without carboplatin, or treatment with Capecitabine, Gemcitabine/Cisplatin. or Pemetrexed/Cisplatin Tumors abutting or providing support for blood vessels Any significant gastrointestinal abnormalities or active bleeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>axitinib</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>anti-angiogenesis</keyword>
	<keyword>VEGF inhibition</keyword>
</DOC>